Search clinical trials for: Vildagliptin

Total 187 results

Damanhour University
Tanta University

Recruiting

Empagliflozin Versus Vildagliptin in CAD Patients With T2DM

Coronary Artery Disease | Type 2 Diabetes

Egypt
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.

Not yet recruiting

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

Allogeneic Stem Cell Transplantation

United States
Bio-innova Co., Ltd

Not yet recruiting

Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets

Healthy Subjects
International Bio service

Not yet recruiting

The Bioequivalence Study of Fixed-dose Combination of Vildagliptin and Metformin HCI 50/1000 mg FCT Under Fed Conditions

Healthy Volunteer
October 6 University

Recruiting

Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome

Poly Cystic Ovary Syndrome

Egypt
Damanhour University

Recruiting

Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients

Type 2 Diabetes

Egypt
MTI University
National Institute of Diabetes and Endocrinology, Egypt

Recruiting

The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Egypt
National Center for Global Health and Medicine,...
Sumitomo Pharma Co., Ltd.

Recruiting

Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Alexandria University

Recruiting

Cognitive Protective Effect of Newer Antidiabetic Drugs

Type 2 Diabetes

Egypt
PegBio Co., Ltd.

Recruiting

Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)

China, Taiwan, Hong Kong
Laboratorios Silanes S.A. de C.V.

Recruiting

Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure

Type 2 Diabetes

Mexico
Sadat City University

Recruiting

Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia

Schizophrenia | Dyslipidemias

Egypt
MedSIR
Novartis

Recruiting

Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients (METALLICA)

Breast Cancer

Spain
Sherief Abd-Elsalam

Recruiting

Clinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM

dm

Egypt
Imperial College London

Recruiting

Noradrenergic Add-on Therapy With Guanfacine (NorAD)

Alzheimer Disease

United Kingdom
Centre Hospitalier Universitaire de Besancon
University Hospital, Strasbourg, France; Centre Hospitalier Universitaire de... and other collaborators

Recruiting

Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period (PRODIG)

Diabetes | Disorder Related to Renal Transplantation

France
Sadat City University

Active, not recruiting

The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients

Major Depressive Disorder

Egypt
ANRS, Emerging Infectious Diseases
University College London Hospitals; Imperial College London; Medical Research... and other collaborators

Active, not recruiting

A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults

Healthy Adults

United Kingdom, Switzerland, France
Reseach Laboratory of Clinical and Experimental...
Société Arabe des Industries Pharmaceutiques SAIPH - Tunisia; Centre National...

Completed

Bioequivalence Study to Compare Metformin / Vildagliptin (850 mg/50 mg) Versus Galvumet®

Fed Conditions

Tunisia
Reseach Laboratory of Clinical and Experimental...
La Société Arabe des Industries Pharmaceutiques-Tunisie; Centre National Chalbi...

Completed

Bioequivalence Study to Compare Metformin / Vildagliptin Versus Galvumet®

Fed Conditions

Tunisia
Damanhour University
Tanta University

Completed

Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD

Coronary Artery Disease | Diabetes Mellitus, Type 2

Egypt
Erasme University Hospital

Terminated

Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

Type 2 Diabetes | Pancreas | Incretinomimetics

Belgium
Milton S. Hershey Medical Center

Terminated

Low-Dose Naltrexone in Combination With Standard Treatment in Women With Endometriosis

Endometriosis

United States
Getz Pharma

Completed

Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus

Type 2 Diabetes

Pakistan
AET Laboratories Private Limited

Completed

The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Assessed.

To Determine Bioequivalence Under Fed Conditions
AET Laboratories Private Limited

Completed

The Study Intends to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Evaluated.

To Determine Bioequivalence Under Fed Conditions
AET Laboratories Private Limited

Completed

The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safeyt Profile of Test Product Compared to Reference Product Will be Assessed.

Diabetes Mellitus
Alexandria University
Eva Pharma

Active, not recruiting

Anti-diabetic Drugs and Fatty Liver Management

Diabetes Mellitus, Type 2 | Fatty Liver, Nonalcoholic

Egypt
National Taiwan University Hospital

Completed

Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients

Thyroid Cancer
Beni-Suef University
Minia University

Completed

Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Egypt
Novartis Pharmaceuticals

Completed

Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Korea, Republic of, Latvia, Peru, Lithuania, Israel, Norway, Finland, Argentina, Austria, Belgium, Germany, Greece, Guatemala, Hungary, India, Italy, Mexico, Poland, Romania, Slovakia, Venezuela
Novartis

Completed

A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin

Diabetes Mellitus, Type 2

United States
Novartis Pharmaceuticals

Completed

Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)

Diabetes Mellitus, Type 2

United States, Hungary, Poland, Germany, France
Novartis Pharmaceuticals

Completed

Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes

Type 2 Diabetes

Japan
University Malaysia Sarawak
Sarawak General Hospital

Completed

DPP4 Inhibitor on Glycemic Variability

Diabetes Mellitus, Type 2

Malaysia
Novartis Pharmaceuticals

Completed

Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients

Diabetes | Renal Impairment

Russian Federation
Novartis Pharmaceuticals

Completed

Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone

Diabetes Mellitus, Type 2

United States, Germany
Novartis

Terminated

Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis Pharmaceuticals

Completed

Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Novartis

Completed

Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Philippines, India, Puerto Rico, Canada, Malaysia, Romania, Slovakia
Novartis Pharmaceuticals

Completed

Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure

Type II Diabetes Mellitus | Congestive Heart Failure

Russian Federation, Singapore, Italy, Czechia, Lithuania, Germany, Guatemala, India, Denmark, Estonia, Slovakia, Romania, Latvia, Greece, Poland
Novartis Pharmaceuticals

Completed

Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Switzerland, Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis

Completed

Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)

Diabetes Mellitus, Type 2 | Renal Insufficiency

United States
Novartis Pharmaceuticals

Completed

Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes

Type 2 Diabetes

Japan
Novartis

Completed

Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency

Diabetes Mellitus, Type 2

United States
Novartis

Completed

Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)

Diabetes Mellitus, Type 2 | Renal Insufficiency

Spain, Canada, France, Germany, Australia, Costa Rica, Finland, Russian Federation, Argentina, India, Norway, Sweden
Novartis

Completed

Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency

Diabetes Mellitus, Type 2

Spain, Argentina, Russian Federation, Norway, India, Sweden, Finland, France, Canada, Germany, Australia, Costa Rica
Novartis Pharmaceuticals

Completed

A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Switzerland

3

Subscribe